Physician

Matthew Orton, M.D.

According to 2025 Medicare claims, Matthew Orton, M.D. (NPI: 1144488917) practices radiation oncology in the Lafayette-West Lafayette, IN market, with the plurality of this provider's patient population coming from Tippecanoe, IN. This provider's primary affiliated billing organization is ARNETT CLINIC, LLC (NPI: 1164490843; TIN: 352030653) and primary practice location at 47904-2848. Orton is affiliated with the Ascension Care Management (ACO ID: A2600), Main Street Rural Health Cedar ACO LLC (ACO ID: A5502), and Indiana University Health ACO, Inc. (ACO ID: D0034), participating under both the MSSP and REACH models.

Orton's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 354 traditional Medicare patients, billed 4,752 HCPCS/CPT codes, and received $675,894 in Medicare payments. The top billing code was 77263 (Complex radiation therapy planning). Part D data shows 447 prescription claims across 163 beneficiaries totaling $49,284 in drug costs, led by Orgovyx (Relugolix). 2018 DME data shows 21 claims. Open Payments data shows 1 records totaling $30. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $711,843 and ending at $675,894. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $3,252 to $49,284. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	233	5,752	$711,843
2016	334	7,292	$1,050,034
2017	334	3,870	$565,437
2018	356	5,257	$758,071
2019	388	5,570	$803,847
2020	371	4,900	$739,932
2021	372	5,744	$862,473
2022	378	5,170	$718,341
2023	420	5,625	$793,055
2024	354	4,752	$675,894

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	44	102	$3,252
2016	82	190	$7,345
2017	74	193	$8,839
2018	96	252	$9,627
2019	116	322	$9,953
2020	138	353	$9,684
2021	145	393	$15,303
2022	150	450	$10,537
2023	166	487	$19,081
2024	163	447	$49,284

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	50	$6,281
2017	N/R	27	$4,430
2018	N/R	21	$3,461
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
77263	Complex radiation therapy planning	87	91	$123
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	95	151	$92
77334	Design and construction of complex radiation treatment device	90	362	$92
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	190	258	$58
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	118	175	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Orgovyx	Relugolix	16	480	$41,484
Tamsulosin Hcl	Tamsulosin Hcl	145	10,358	$2,256
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	24	182	$714
Megestrol Acetate	Megestrol Acetate	15	729	$665
Venlafaxine Hcl Er	Venlafaxine Hcl	39	2,711	$502

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	1	$30	PROGENICS PHARMACEUTICALS, INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Matthew Orton, M.D.?

Tedicare shows public-source Medicare data for Matthew Orton, M.D. (NPI 1144488917), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Matthew Orton, M.D. have ACO affiliation data?

Matthew Orton, M.D. is shown with ACO affiliation data for Ascension Care Management (MSSP, ACO ID A2600), Main Street Rural Health Cedar ACO LLC (MSSP, ACO ID A5502), and Indiana University Health ACO, Inc. (REACH, ACO ID D0034).

What billing organization is linked to Matthew Orton, M.D.?

Matthew Orton, M.D. is linked to ARNETT CLINIC, LLC (billing NPI 1164490843) in the available physician profile data.

Does Matthew Orton, M.D. have Open Payments data?

Matthew Orton, M.D. has 1 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.